These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11815500)

  • 1. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.
    Lamotte M; Annemans L; Lefever A; Nechelput M; Masure J
    Diabetes Care; 2002 Feb; 25(2):303-8. PubMed ID: 11815500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat in responding obese type 2 diabetic patients: meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland.
    Ruof J; Golay A; Berne C; Collin C; Lentz J; Maetzel A
    Int J Obes (Lond); 2005 May; 29(5):517-23. PubMed ID: 15738932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach.
    Hertzman P
    Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of treatment with orlistat in Italian obese patients.
    Iannazzo S; Zaniolo O; Pradelli L
    Curr Med Res Opin; 2008 Jan; 24(1):63-74. PubMed ID: 18021491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat for the treatment of obesity: rapid review and cost-effectiveness model.
    Foxcroft DR; Milne R
    Obes Rev; 2000 Oct; 1(2):121-6. PubMed ID: 12119985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.
    van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM
    Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat: a review of its use in the management of patients with obesity.
    Curran MP; Scott LJ
    Drugs; 2004; 64(24):2845-64. PubMed ID: 15563254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.".
    Edelsberg J; Weycker D; Oster G
    Diabetes Care; 2002 Oct; 25(10):1899-900. PubMed ID: 12351513
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat for the treatment of obesity: cost utility model.
    Foxcroft DR
    Obes Rev; 2005 Nov; 6(4):323-8. PubMed ID: 16246217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
    Neovius M; Narbro K
    Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity drug therapy.
    Baretić M
    Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pharmacotherapy to reduce obesity.
    Veerman JL; Barendregt JJ; Forster M; Vos T
    PLoS One; 2011; 6(10):e26051. PubMed ID: 22046255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.